CD25-bindende Moleküle

Patent europeic · EP0449769 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP0449769
Numer da la dumonda
EP91810166
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
13-03-1991
Publitgà
02-10-1991
Concedì
15-12-1993
Stritgà
12-03-2011
Motiv
Durada maximala cuntanschida
Classas IPC
C07K 15/28 (1990.01)
C12N 15/13 (2006.01)
C12P 21/08 (2006.01)
A61K 39/395 (2006.01)
Prioritad
GB A 9005962 16.03.1990
GB A 9019323 05.09.1990
Lingua da l’annunzia
englais
Funtauna
Swissreg

Certificats cumplementars da protecziun

In certificat prolunghescha la protecziun dal patent per in medicament u in product da protecziun da plantas admess en Svizra.

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 14-03-2011

    Durada maximala cuntanschida

    Published in Swissreg on 14.03.2011

  2. 15-05-1997

    Adressa midada

    Owner
    Sandoz AG, Lichtstrasse 35, 4002 Basel, Royal Free Hospital School of, Medicine, Rowland Hill Street, London NW3, United Kingdom → Royal Free Hospital School of, Medicine, Rowland Hill Street, London NW3, United Kingdom, Novartis AG, Schwarzwaldallee 215, 4058 Basel

    Published in PIDTJ No 9 in 1997

  3. 31-01-1994

    Concedì

    Published in PIDTJ No 2 in 1994

Partidas

Inventur

Amlot, Peter Lloyd

London N9 9BL, GB

Akbar, Arne Nalpon

Richmond, Surrey TW94LD, GB

Heinrich, Günther

CH-4125 Riehen

Cammisuli, Salvatore

CH-4153 Reinach

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.